Healthcare Services

Global Infectious Disease Clinical Trials Market Forecast Highlighting Expansion And Competitive Dynamics

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Size Is Forecasted For The Infectious Disease Clinical Trials Market By 2030 Based On Its 2026 Value?

The infectious disease clinical trials market has experienced robust growth in recent years. It is anticipated to increase from $15.1 billion in 2025 to $16.13 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.8%. The historical expansion can be linked to the escalating global infectious disease burden, enhanced funding for vaccine development, the proliferation of multinational clinical trial networks, the implementation of digital trial management systems, and surging public health research initiatives.

The infectious disease clinical trials market is anticipated to experience robust growth in the upcoming years, projected to reach $21.25 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.1%. This expansion during the forecast period is attributed to escalating investments in pandemic preparedness, the increasing application of AI-assisted patient recruitment, the broader implementation of global trial decentralization, a heightened focus on accelerated regulatory approvals, and the growing integration of digital biomarkers. Significant trends foreseen for the forecast period include the rising adoption of data-driven trial design, increased utilization of decentralized clinical trial models, the deepening integration of real-world evidence, the expansion of adaptive trial methodologies, and an enhanced focus on rapid pathogen response.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=29097&type=smp

Which Major Factors Are Contributing To The Development Of The Infectious Disease Clinical Trials Market?

The expansion of healthcare infrastructure is anticipated to fuel the progress of the infectious disease clinical trials market moving ahead. This infrastructure encompasses physical facilities, medical technology, equipment, and a skilled workforce crucial for delivering healthcare services and facilitating disease prevention, diagnosis, and treatment. The development of healthcare infrastructure is increasing due to a higher demand for sophisticated medical services, the escalating prevalence of new and intricate diseases, and the necessity for adequately equipped facilities and proficient healthcare personnel to ensure prompt diagnosis, treatment, and preventive measures. Such infrastructure directly boosts clinical trial capabilities by offering state-of-the-art medical facilities, specialized apparatus, and improved research capacities, all vital for executing thorough infectious disease investigations. As an illustration, the American Hospital Association, a US-based non-profit organization, forecasts that by January 2025, the total number of hospitals in the United States will reach 6,093, indicating a steady increase in healthcare facilities across the nation. Consequently, the growing healthcare infrastructure is a significant impetus for the expansion of the infectious disease clinical trials market.

Which Segment Divisions Form The Structure Of The Infectious Disease Clinical Trials Market?

The infectious disease clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Indication: Human Immunodeficiency Virus, Hepatitis, Influenza, Tuberculosis, Malaria, Coronavirus Disease Of 2019 (COVID-19), Other Indications

3) By Study Design: Randomized Controlled Trials, Open Label Studies, Double Blind Studies, Observational Studies, Cohort Studies

4) By Drug Type: Antibiotics, Antivirals, Antifungals, Vaccines, Combination Therapies

5) By End-User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Other End-Users

Subsegments:

1) By Phase I: Healthy Volunteer Trials, Dose Escalation Studies, Safety And Tolerability Studies, Pharmacokinetic And Pharmacodynamic Studies

2) By Phase II: Early Efficacy Studies, Proof Of Concept Studies, Patient Population Specific Studies, Short Term Safety Studies

3) By Phase III: Large Scale Efficacy Trials, Comparative Effectiveness Studies, Multi Center Clinical Trials, Extended Safety And Tolerability Studies

4) By Phase IV: Post Marketing Surveillance Studies, Long Term Safety Studies, Real World Evidence Studies, Special Population Studies

What Trends Are Affecting The Growth Of The Infectious Disease Clinical Trials Market?

Leading organizations within the infectious disease clinical trials market are concentrating on developing advanced research initiatives, such as phase 3 trials for antibiotic candidates, to help uncover rare side effects and confirm optimal dosages. A phase 3 trial of antibiotic candidates is a late-stage investigation that tests the medication in a large patient population to assess its safety, efficacy, and comparison to existing treatments before gaining approval for use. For instance, in May 2025, Roche, a Switzerland-based pharmaceutical company, initiated a Phase 3 clinical trial for zosurabalpin, an innovative tethered macrocyclic peptide antibiotic specifically engineered to combat CRAB, a significant cause of severe hospital infections globally. Zosurabalpin’s unique characteristic lies in its novel mechanism of action, which obstructs the transport of lipopolysaccharide essential for constructing the bacterial outer membrane, with no resistance observed so far. This global trial will encompass approximately 400 patients to evaluate its safety and effectiveness when compared to standard treatments. Preliminary research has indicated potent activity against multidrug-resistant bacteria, excellent tolerability, and promising pharmacokinetic properties. This places Zosurabalpin as a potentially groundbreaking remedy in tackling the urgent challenge of antibiotic resistance.

Who Are The Major Companies Operating In The Infectious Disease Clinical Trials Market?

Major companies operating in the infectious disease clinical trials market are GlaxoSmithKline plc (GSK), Pfizer Inc, Moderna Inc, Novartis AG, Sanofi S.A., AstraZeneca plc, Merck & Co Inc, Gilead Sciences Inc, AbbVie Inc, Eli Lilly and Company, Bristol Myers Squibb Company, Roche Holding AG, Bayer AG, Takeda Pharmaceutical Company Limited, CSL Limited, Regeneron Pharmaceuticals Inc, Biogen Inc, Amgen Inc, Inovio Pharmaceuticals Inc, Dynavax Technologies Corporation, Valneva SE, Emergent BioSolutions Inc, Vir Biotechnology Inc, International AIDS Vaccine Initiative, VBI Vaccines Inc, Otsuka Pharmaceutical Co Ltd, Daiichi Sankyo Company Limited, Shionogi & Co Ltd, Astellas Pharma Inc, Eisai Co Ltd, Sun Pharmaceutical Industries Ltd, Glenmark Pharmaceuticals Ltd, Bharat Biotech International Limited, Laurus Labs Limited, Sarepta Therapeutics Inc, Alnylam Pharmaceuticals Inc, Intellia Therapeutics Inc, Sangamo Therapeutics Inc, Excision BioTherapeutics Inc, Atara Biotherapeutics Inc, Adaptive Biotechnologies Corporation, ImmunityBio Inc, Enanta Pharmaceuticals Inc, Iterum Therapeutics plc, Spero Therapeutics Inc, Venatorx Pharmaceuticals Inc, Vaxart Inc, Immunovant Inc, Tonix Pharmaceuticals Holding Corp, Genentech Infectious Diseases Unit

Access The Complete Infectious Disease Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/report/infectious-disease-clinical-trials-global-market-report

Which Area Represents The Largest Portion Of The Infectious Disease Clinical Trials Market?

North America was the largest region in the infectious disease clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Infectious Disease Clinical Trials Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=29097&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Clinical Trials Market 2026, By The Business Research Company

Hospital Acquired Infection Control Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infection-control-global-market-report

Infection Prevention Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/infection-prevention-global-market-report

Infection Control Supplies Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/infection-control-supplies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795